Phillip G. Monroy
Research Subjects
Phillip G. Monroy has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Marcio A. da Fonseca
1 shared publication
Latest Publications
- 1 January 2007
- Vol. 89 (1) , 32, 34-6
The age-1 dental visit and the dental home; a model for early childhood caries prevention.
Early childhood caries (ECC) has been reported by the Centers for Disease Control and Prevention to be the most prevalent infectious disease in our nation's children. Despite great strides in the reduction in caries in the last few decades, preventive efforts for very young children are often not instituted early enough to be effective. The general public and many dentists feel that children don't need to see a dentist until the age of 3 years. Too often, however, maternal transmission of cariogenic bacteria has already occurred and destruction of the dental hard tissues has begun. Restorative care for young children can be difficult, expensive, and the need for it is almost entirely preventable. In an effort to identify those patients at high risk for ECC, the American Academy of Pediatric Dentistry and the American Academy of Pediatrics have issued policy statements regarding oral health risk assessment timing and the establishment of a "dental home" by the age of 1 year. By identifying at-risk patients and directing aggressive preventive strategies at them, we can decrease the prevalence of ECC. This article reviews the age-1 dental visit and the concept of the dental home, and provides general practitioners with a method to introduce it into their practice.
- 1 January 2007
- Vol. 89 (1) , 32, 34-6
The age-1 dental visit and the dental home; a model for early childhood caries prevention.
Early childhood caries (ECC) has been reported by the Centers for Disease Control and Prevention to be the most prevalent infectious disease in our nation's children. Despite great strides in the reduction in caries in the last few decades, preventive efforts for very young children are often not instituted early enough to be effective. The general public and many dentists feel that children don't need to see a dentist until the age of 3 years. Too often, however, maternal transmission of cariogenic bacteria has already occurred and destruction of the dental hard tissues has begun. Restorative care for young children can be difficult, expensive, and the need for it is almost entirely preventable. In an effort to identify those patients at high risk for ECC, the American Academy of Pediatric Dentistry and the American Academy of Pediatrics have issued policy statements regarding oral health risk assessment timing and the establishment of a "dental home" by the age of 1 year. By identifying at-risk patients and directing aggressive preventive strategies at them, we can decrease the prevalence of ECC. This article reviews the age-1 dental visit and the concept of the dental home, and provides general practitioners with a method to introduce it into their practice.
- 1 January 2006
- Published by Wiley in Special Care in Dentistry
- Vol. 26 (1) , 37-39
The Use of Botulinum Toxin‐A in the Treatment of Severe Bruxism in a Patient with Autism: A Case Report
This case report describes an alternative method for reducing bruxism in a special needs patient who was not a candidate for an intraoral appliance. Bruxism is often seen in patients with special needs and can result in excessive dental wear, temporomandibular joint pain, avulsion of teeth and other problems. Current methods of management are not typically effective in this population because most require patient compliance. An 11‐year‐old male diagnosed with autism and Bannayan‐Zonana syndrome received bilateral injections of botulinum toxin type‐A (Botox® Allergan Pharmaceuticals, Irvine CA) in the masseter muscle. The patient's condition was followed up via post‐operative telephone interviews with the parents for 60 days. A reduction in the frequency and severity of bruxism was reported. The only side effects noted were soreness at the injection site and mild, temporary drooling. Although further research is required to determine the optimal doses and injection frequency, botulinum toxin type‐A appears to be an alternative method for controlling bruxism in the special needs population.
- 1 January 2006
- Published by Wiley in Special Care in Dentistry
- Vol. 26 (1) , 37-39
The Use of Botulinum Toxin‐A in the Treatment of Severe Bruxism in a Patient with Autism: A Case Report
This case report describes an alternative method for reducing bruxism in a special needs patient who was not a candidate for an intraoral appliance. Bruxism is often seen in patients with special needs and can result in excessive dental wear, temporomandibular joint pain, avulsion of teeth and other problems. Current methods of management are not typically effective in this population because most require patient compliance. An 11‐year‐old male diagnosed with autism and Bannayan‐Zonana syndrome received bilateral injections of botulinum toxin type‐A (Botox® Allergan Pharmaceuticals, Irvine CA) in the masseter muscle. The patient's condition was followed up via post‐operative telephone interviews with the parents for 60 days. A reduction in the frequency and severity of bruxism was reported. The only side effects noted were soreness at the injection site and mild, temporary drooling. Although further research is required to determine the optimal doses and injection frequency, botulinum toxin type‐A appears to be an alternative method for controlling bruxism in the special needs population.